CASI Pharmeceuticals

Board of Directors

Wei-Wu He, Ph.D., Chairman
Dr. He has been a Director of the Company and was appointed Executive Chairman in February 2012. Dr. He is currently the CEO and Chairman of OriGene Technologies, Inc. He also is the founder and General Partner of Emerging Technology Partners, LLC (ETP), a life sciences focused venture fund established since 2000. Dr. He has been involved in founding or funding over 20 biotech companies throughout his career, some of which went on to be acquired by significantly larger firms. In the earlier part of his career, Dr. He was one of the first few scientists at Human Genome Sciences, and prior to that, was a research fellow at Massachusetts General Hospital and Mayo Clinic. Dr. He is an author to more than 25 research publications and inventor of over 30 issued patents.

James Huang
Mr. Huang has been a Director of the Company since April 2013. Mr. Huang is currently Managing Partner of Kleiner Perkins Caufield Byers China and General Partner of KPCB China Fund II, LP, which invested in the Company’s 2013 financing. Prior to joining Kleiner Perkins, from 2007-2011 he was Managing Partner at Vivo Ventures LLC, a venture capital firm specializing in life science investments. Mr. Huang has over 20 years of experience in the pharmaceutical and biopharmaceutical industry. During this time, he has held senior roles in business development, sales, marketing and R&D with Anesiva, Inc., Tularik Inc, GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. Mr. Huang is Chairman of the Board at Kindstar Global, JHL Biotech and XW Laboratory and Director at GenScript, ChiralQuest, Zenesis and CVie Therapeutics. Mr. Huang received a B.S. degree in chemical engineering from the University of California, Berkley and a M.B.A. from the Stanford Graduate School of Business.

Quan Zhou, Ph.D.
Dr. Zhou has been a director of the Company since June 2016. Dr. Zhou served as the president of IDG Technology Venture Investment Inc. from mid-1990’s until 2012. He has been the managing member of IDG Technology Venture Investments, LP and its successor funds since 2000 and the director of various IDG-Accel China funds since 2005. He currently also serves as the director of IDG China Venture Capital Fund IV L.P. and IDG China Capital Fund III L.P.. He serves on the boards of public companies, including Fang Holdings Ltd. (also known as Soufun Holdings Limited) since 1999, Xunlei Limited since 2006, and Yirendai Limited since 2015, and serves on the boards of various private companies, including Superdata Software Holdings Limited, Memsic Inc. and Circle Internet Financial Limited. He has won awards from NASA and holds two U.S. patents in fiber optic devices. Benefiting from more than 20 years of successful financing, business and operation experience, he has established close connections with numerous IT companies and entrepreneurial communities in both China and the United States. He received a Ph.D. in Fiber Optics from Rutgers University in 1989, a Master’s Degree in Chemical Physics from the Chinese Academy of Science in 1985, and a Bachelor’s Degree in Chemical Science from China Science and Technology University in 1982. Dr. Zhou’s qualifications to serve on the Board of Directors, as well as serving as the Chair of the Compensation Committee, include his substantial business experience, particularly in China.

Rajesh C. Shrotriya, MD
Dr. Shrotriya has been a Director of the Company since September 2014. He is currently the Chairman and Chief Executive Officer of Spectrum Pharmaceuticals. Dr. Shrotriya joined Spectrum in 2000 as President and Chief Operating Officer and was appointed Chief Executive Officer in August 2002. In this capacity he has spearheaded major changes in business strategy and coordinated structural reorganization culminating in the formation of Spectrum Pharmaceuticals, Inc. Prior to joining Spectrum, Dr. Shrotriya was Executive Vice President and Chief Scientific Officer for SuperGen, Inc. and Vice President, Medical Affairs and Vice President, Chief Medical Officer at MGI Pharma, Inc. For 18 years he held various positions at Bristol-Myers Squibb Company, the most recent being Executive Director Worldwide CNS Clinical Research.

Y. Alexander Wu, Ph.D.
Dr. Wu has been a Director of the Company since April 2013. Dr. Wu is an independent consultant. He co-founded and was Chief Executive Officer of Crown Bioscience, Inc., a drug discovery and preclinical research organization in the oncology sector with over 600 employees from 2006 to 2016. Before co-founding Crown Bioscience, Dr. Wu was Chief Business Officer of Starvax International Inc., a biopharmaceutical R&D company focusing on the development of novel therapeutic drugs for the treatment of infectious disease and cancer. Prior to Starvax, he was the Head of Asian Operations with Burrill & Company, a life science venture capital and merchant bank. Dr. Wu also co-founded and was Chief Operating Officer of Unimicro Technologies, a life science instrumentation company. He started his career with Hoffmann-La Roche, where he was Manager of Business Development and Strategic Planning. Dr. Wu obtained his B.S. in biochemistry from Fudan University, China, a M.S. in Biochemistry from the University of Illinois, and a Ph.D. in molecular cell biology and MBA from the University of California, Berkeley.

Franklin C. Salisbury, Jr.
Mr. Salisbury has been a Director of the Company since June 2014. Since 1998, Mr. Salisbury has been President of the National Foundation for Cancer Research (NFCR), an organization that supports healthcare companies and research institutions in order to accelerate new approaches to preventing, diagnosing and treating cancer. Under his leadership, NFCR has forged greater collaboration among scientists at universities, research hospitals and pharmaceutical companies in the U.S. and China in an effort to bring new and innovative care to cancer patients. Mr. Salisbury also led NFCR to launch several research consortia that have enabled cancer researchers to pool their resources and reduce duplicative efforts, thereby accelerating discoveries being made and reducing the cost of achieving them. Mr. Salisbury holds a B.A. in economics from Yale, a Juris Doctor, J.D., from the University of Georgia School of Law, a Masters of Arts degree from the University of Chicago, and an M.Div. from Yale Divinity School.

Ken K. Ren, Ph.D.
Dr. Ren joined CASI Pharmaceuticals in April 2012, was appointed Chief Executive Officer in April 2013, and was elected to the Board of Directors in December 2014. Over the past 15 years, prior to CASI, Dr. Ren has been a founder and/or key executive in several start-up companies with business operations in both the U.S. and China. He was President of Accelovance (China), a clinical contract research organization, a co-founder and CEO of ImmunoVentis, a cell-based immunotherapy company, Novemed, a drug development company, and of China Innovation Center for Life Science (U.S.A.) Corp., a consulting company. Dr. Ren was also a Chief Investment Director of CCBI Healthcare Fund of China Construction Bank, responsible for private equity investment in China’s healthcare industry. Dr. Ren was a research scientist at Pfizer from 1993–1995 and an Immunology Research Fellow at Rockefeller University from 1990–1993. He received his medical degree at the Shandong University School of Medicine in China in 1986 and a Ph.D. in immunology from the State University of New York at Buffalo in 1990 and a Certificate of Completion of Executive Business Management Program in Tsinghua University, Beijing China.

Committee Membership

Director Audit Compensation
Wei-Wu He, Chairman
James Huang X (chairman and financial expert)
Quan Zhou X (chairman)
Ken K. Ren
Franklin C. Salisbury, Jr. X X
Rajesh C. Shrotriya
Y. Alexander Wu X X

About Us

A leading US-headquartered, NASDAQ-listed, biopharmaceutical company targeting the global market, with a focus on China.

Learn More

In the News

CASI's turnaround turns eastward; firm seeks to be Celgene of China

Read Article →


Clinical Safety and Efficacy of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated, Locally Advanced or Metastatic Triple-Negative Breast Cancer

Download →


Rodman & Renshaw 19th Annual Global Investment Conference

Download →